MILLICENT ANIMLEY: Open Payments
NPI 1760104913 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,792 in 164 payments from 24 companies in 2025. Trend: 2023 $0 · 2024 $18 · 2025 $3,792
Food & beverage: $3,708Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 46 | $753 |
| Janssen Biotech, Inc. | 21 | $622 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $372 |
| Madrigal Pharmaceuticals | 8 | $300 |
| QOL Medical, LLC | 9 | $230 |
| PFIZER INC. | 7 | $220 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $197 |
| Braintree Laboratories, Inc. | 3 | $150 |
| Ipsen Biopharmaceuticals, Inc | 5 | $118 |
| Lilly USA, LLC | 5 | $110 |
Products named: TREMFYA, RINVOQ, ENTYVIO, REZDIFFRA, Sucraid, XIFAXAN, VELSIPITY, VIBERZI.
Industry payments across DC — which companies pay providers there.
